Also known as LY3437943
Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
Retatrutide is an Eli Lilly–developed triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials reported ~24% mean weight reduction at 48 weeks at the highest dose.
Retatrutide (development code LY3437943) is an investigational single peptide that activates three receptors — GIP, GLP-1, and glucagon. Adding glucagon-receptor agonism to the incretin pair is studied as a way to increase energy expenditure and lipolysis on top of the insulinotropic and satiety effects of GIP and GLP-1.
Developed by Eli Lilly, it remains investigational and has not been approved. Phase 2 results reported notably large mean weight reductions at the highest doses over roughly a year, placing it among the most closely watched "triple agonist" candidates in late-stage metabolic research.
GIP + GLP-1 (insulinotropic, satiety) plus glucagon (energy expenditure, lipolysis).
Behind every vial of Retatrutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Retatrutide, specifically, is brought into being.
On paper, Retatrutide is C221H342N46O68 — about 4,731.5 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Retatrutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Retatrutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Retatrutide proves itself: identity confirmed by mass spectrometry against its ~4,731.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Retatrutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Retatrutide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Retatrutide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Retatrutide is an investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors, studied in late-stage trials for obesity and type 2 diabetes.
It adds glucagon-receptor activation — studied for increased energy expenditure and fat breakdown — to the insulinotropic and satiety effects of GIP and GLP-1.
No. It is investigational and has not received FDA approval; all data comes from clinical research.
Eli Lilly. This page is a research and educational reference, not medical advice or an offer for sale.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.